Search research articles
Contact Us
Filters
Showing results (1-10 of 265) with videos related to
Page
of 27
Sort By:
The American Journal of Psychiatry
|
March 1, 2025
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?
Daniel C Javitt
The American Journal of Managed Care
|
September 3, 2014
Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: exploring the treatment landscape
Daniel C Javitt
The American Journal of Psychiatry
|
April 2, 2016
Biotypes in Psychosis: Has the RDoC Era Arrived?
Daniel C Javitt
Current Opinion in Investigational Drugs (London, England : 2000)
|
August 21, 2002
Glycine modulators in schizophrenia
Daniel C Javitt
Trends in Cognitive Sciences
|
March 26, 2002
Madness in the garden or worm in the apple?
Daniel C. Javitt
Biological Psychiatry
|
February 13, 2018
Excitatory Amino Acids in Schizophrenia: Both What You Have, and What You Do With Them
Daniel C Javitt
Annual Review of Clinical Psychology
|
March 31, 2009
When doors of perception close: bottom-up models of disrupted cognition in schizophrenia
Daniel C Javitt
Annals of the New York Academy of Sciences
|
February 28, 2015
Neurophysiological models for new treatment development in schizophrenia: early sensory approaches
Daniel C Javitt
Current Topics in Behavioral Neurosciences
|
April 1, 2025
Disturbances in Auditory and Visual Perceptual Function in Schizophrenia: Patterns, Causes, and Consequences
Daniel C Javitt
Schizophrenia Research. Cognition
|
November 9, 2017
Meeting overview: Sensory perception and schizophrenia, Lausanne, Switzerland June 31-July 1, 2014
Daniel C Javitt
Page
of 27
Search research articles
Search
Showing results (1-10 of 265) with videos related to
Sort By:
Page
of 27
The American Journal of Psychiatry
|
March 1, 2025
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?
Daniel C Javitt
The American Journal of Managed Care
|
September 3, 2014
Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: exploring the treatment landscape
Daniel C Javitt
The American Journal of Psychiatry
|
April 2, 2016
Biotypes in Psychosis: Has the RDoC Era Arrived?
Daniel C Javitt
Current Opinion in Investigational Drugs (London, England : 2000)
|
August 21, 2002
Glycine modulators in schizophrenia
Daniel C Javitt
Trends in Cognitive Sciences
|
March 26, 2002
Madness in the garden or worm in the apple?
Daniel C. Javitt
Biological Psychiatry
|
February 13, 2018
Excitatory Amino Acids in Schizophrenia: Both What You Have, and What You Do With Them
Daniel C Javitt
Annual Review of Clinical Psychology
|
March 31, 2009
When doors of perception close: bottom-up models of disrupted cognition in schizophrenia
Daniel C Javitt
Annals of the New York Academy of Sciences
|
February 28, 2015
Neurophysiological models for new treatment development in schizophrenia: early sensory approaches
Daniel C Javitt
Current Topics in Behavioral Neurosciences
|
April 1, 2025
Disturbances in Auditory and Visual Perceptual Function in Schizophrenia: Patterns, Causes, and Consequences
Daniel C Javitt
Schizophrenia Research. Cognition
|
November 9, 2017
Meeting overview: Sensory perception and schizophrenia, Lausanne, Switzerland June 31-July 1, 2014
Daniel C Javitt
Page
of 27